This house believes that NTCP models should be leading our clinical decision-making
Andrew Hope,
Canada;
Laura Cella,
Italy
In radiation oncology, treatment decisions require balancing therapeutic efficacy with the risk of toxicity. Normal Tissue Complication Probability (NTCP) models offer a quantitative framework for estimating treatment-related side effects, potentially enabling safer, more personalized care. However, whether they should take the lead in clinical decision-making remains a matter of debate.
Arguing for the motion, Markus Alber and Hans Langendijk will advocate for NTCP models as essential tools for guiding patient management. Opposing them, Tiziana Rancati and Ivan Vogelius will highlight model limitations and question their reliability.
The stage is set for a compelling debate—but who has the stronger arguments? That’s for you, the audience, to decide!
Debate
Physics
GI